SG153039A1 - Crystalline polymorphic forms of monosodium n-[8- (2hydroxybenzoyl)amino]caprylate - Google Patents
Crystalline polymorphic forms of monosodium n-[8- (2hydroxybenzoyl)amino]caprylateInfo
- Publication number
- SG153039A1 SG153039A1 SG200903067-7A SG2009030677A SG153039A1 SG 153039 A1 SG153039 A1 SG 153039A1 SG 2009030677 A SG2009030677 A SG 2009030677A SG 153039 A1 SG153039 A1 SG 153039A1
- Authority
- SG
- Singapore
- Prior art keywords
- caprylate
- monosodium
- amino
- polymorphic forms
- crystalline polymorphic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56947604P | 2004-05-06 | 2004-05-06 | |
US61941804P | 2004-10-15 | 2004-10-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG153039A1 true SG153039A1 (en) | 2009-06-29 |
Family
ID=35320672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200903067-7A SG153039A1 (en) | 2004-05-06 | 2005-05-06 | Crystalline polymorphic forms of monosodium n-[8- (2hydroxybenzoyl)amino]caprylate |
Country Status (15)
Country | Link |
---|---|
US (6) | US8636996B2 (de) |
EP (3) | EP1773351B1 (de) |
JP (1) | JP4903690B2 (de) |
CN (6) | CN102040537A (de) |
AU (1) | AU2005240213B8 (de) |
BR (1) | BRPI0510231A (de) |
CA (2) | CA2563681C (de) |
EA (1) | EA013518B1 (de) |
ES (3) | ES2879880T3 (de) |
HK (5) | HK1153731A1 (de) |
IL (1) | IL178677A (de) |
MX (1) | MXPA06012842A (de) |
NZ (1) | NZ550890A (de) |
SG (1) | SG153039A1 (de) |
WO (1) | WO2005107462A2 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8030271B2 (en) | 2005-07-05 | 2011-10-04 | Emisphere Technologies, Inc. | Compositions and methods for buccal delivery of human growth hormone |
WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
EP2040718B1 (de) * | 2006-06-28 | 2017-12-27 | Emisphere Technologies, Inc. | Galliumnitrid-formulierungen |
WO2008014232A2 (en) * | 2006-07-24 | 2008-01-31 | Emisphere Technologies, Inc. | Pharmaceutical formulations for the treatment of alzheimer's disease |
US10875826B2 (en) | 2006-09-07 | 2020-12-29 | Emisphere Technologies, Inc. | Process for the manufacture of SNAC (salcaprozate sodium) |
DK2215047T3 (da) | 2007-11-02 | 2014-02-03 | Emisphere Tech Inc | Fremgangsmåde til behandling af vitamin b12-mangel |
EP2461803B1 (de) * | 2009-08-03 | 2018-10-17 | Emisphere Technologies, Inc. | Schnell wirkende naproxenzusammensetzung mit reduzierter wirkung auf magen und darm |
CA2790708A1 (en) * | 2010-02-24 | 2011-09-01 | Emisphere Technologies, Inc. | Oral b12 therapy |
RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
CN106117344B (zh) | 2011-04-12 | 2020-11-03 | 诺沃—诺迪斯克有限公司 | 双酰化glp-1衍生物 |
US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
ES2715308T3 (es) | 2012-03-22 | 2019-06-03 | Novo Nordisk As | Composiciones que comprenden un agente de suministro y su preparación |
EP2863895B1 (de) * | 2012-06-20 | 2021-04-14 | Novo Nordisk A/S | Tablettenformulierung enthaltend ein peptid und einen adsorptionsvermittler |
AU2013318338B2 (en) | 2012-09-21 | 2017-05-25 | Intensity Therapeutics, Inc | Method of treating cancer |
US10954824B2 (en) | 2016-12-19 | 2021-03-23 | General Electric Company | Systems and methods for controlling drum levels using flow |
EP3746111B1 (de) | 2018-02-02 | 2023-07-19 | Novo Nordisk A/S | Feste zusammensetzungen mit einem glp-1-agonisten, einem salz aus n-(8-(2-hydroxybenzoyl)amino)caprylsäure und einem schmierstoff |
CN111517980B (zh) * | 2020-05-14 | 2021-02-09 | 台州浦凯医药科技有限公司 | N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途 |
KR20230015414A (ko) * | 2020-05-29 | 2023-01-31 | 항저우 사이윈드 바이오사이언시즈 컴퍼니 리미티드 | 칼륨 n-[8-(2-히드록시벤조일)아미노]옥타노에이트결정 다형체 및 이의 제조 방법과 용도 |
JP2022094481A (ja) * | 2020-12-15 | 2022-06-27 | 大阪瓦斯株式会社 | ヒドロキシアルカン酸結晶の製造方法及びヒドロキシアルカン酸の結晶多形体 |
AU2022311059A1 (en) | 2021-07-16 | 2024-01-18 | Novo Nordisk A/S | Sodium n-(8-(2- hydroxybenzoyl)amino)caprylate polymorphic form a |
CN115108936A (zh) * | 2022-07-29 | 2022-09-27 | 成都普康唯新生物科技有限公司 | 无水体系制备8-(2-羟基苯甲酰胺基)辛酸钠无水晶型的方法 |
CN117466765B (zh) * | 2023-12-27 | 2024-03-15 | 成都道合尔医药技术有限公司 | 8-(2-羟基苯甲酰胺基)辛酸钠及其合成方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4421685A (en) | 1980-03-27 | 1983-12-20 | Eli Lilly And Company | Process for producing an insulin |
US5534488A (en) | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
US5866536A (en) * | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
CN1151836C (zh) * | 1995-03-31 | 2004-06-02 | 艾米斯菲尔技术有限公司 | 用作传送活性剂的化合物和组合物 |
ES2235854T3 (es) * | 1999-04-05 | 2005-07-16 | Emisphere Technologies, Inc. | Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos. |
JP4707931B2 (ja) * | 2000-08-18 | 2011-06-22 | エミスフェアー・テクノロジーズ・インク | 活性剤デリバリー用化合物および組成物 |
US7138546B2 (en) * | 2000-08-18 | 2006-11-21 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
CA2438848C (en) * | 2001-03-01 | 2011-05-03 | Emisphere Technologies, Inc. | Compositions for delivering bisphosphonates |
JP2002332231A (ja) * | 2001-03-06 | 2002-11-22 | Jiro Takada | γ−CEHC送達剤 |
-
2005
- 2005-05-06 CN CN2010105935750A patent/CN102040537A/zh active Pending
- 2005-05-06 ES ES19180925T patent/ES2879880T3/es active Active
- 2005-05-06 CA CA2563681A patent/CA2563681C/en not_active Expired - Fee Related
- 2005-05-06 BR BRPI0510231-6A patent/BRPI0510231A/pt not_active Application Discontinuation
- 2005-05-06 CN CN2010105936039A patent/CN102040538B/zh active Active
- 2005-05-06 JP JP2007511696A patent/JP4903690B2/ja active Active
- 2005-05-06 ES ES05748026T patent/ES2729825T3/es active Active
- 2005-05-06 EP EP05748026.1A patent/EP1773351B1/de active Active
- 2005-05-06 CA CA2897225A patent/CA2897225C/en not_active Expired - Fee Related
- 2005-05-06 EP EP16161529.9A patent/EP3058944B1/de active Active
- 2005-05-06 SG SG200903067-7A patent/SG153039A1/en unknown
- 2005-05-06 CN CN2010105934921A patent/CN102001962B/zh active Active
- 2005-05-06 WO PCT/US2005/016126 patent/WO2005107462A2/en active Application Filing
- 2005-05-06 MX MXPA06012842A patent/MXPA06012842A/es active IP Right Grant
- 2005-05-06 CN CN201010593589.2A patent/CN102001963B/zh active Active
- 2005-05-06 CN CN2010105934599A patent/CN102040536B/zh active Active
- 2005-05-06 AU AU2005240213A patent/AU2005240213B8/en not_active Ceased
- 2005-05-06 US US11/568,753 patent/US8636996B2/en active Active
- 2005-05-06 EA EA200602066A patent/EA013518B1/ru unknown
- 2005-05-06 ES ES16161529T patent/ES2739500T3/es active Active
- 2005-05-06 NZ NZ550890A patent/NZ550890A/en not_active IP Right Cessation
- 2005-05-06 CN CN2010105934391A patent/CN102040535B/zh active Active
- 2005-05-06 EP EP19180925.0A patent/EP3572086B1/de active Active
-
2006
- 2006-10-17 IL IL178677A patent/IL178677A/en active IP Right Grant
-
2011
- 2011-08-16 HK HK11108635.1A patent/HK1153731A1/xx not_active IP Right Cessation
- 2011-08-16 HK HK11108634.2A patent/HK1153730A1/xx not_active IP Right Cessation
- 2011-11-03 HK HK11111869.2A patent/HK1157317A1/xx not_active IP Right Cessation
- 2011-11-03 HK HK11111873.6A patent/HK1157737A1/xx not_active IP Right Cessation
- 2011-11-03 HK HK11111870.9A patent/HK1157318A1/xx not_active IP Right Cessation
-
2013
- 2013-12-23 US US14/138,787 patent/US9321719B2/en active Active
-
2016
- 2016-02-22 US US15/049,313 patent/US9750710B2/en active Active
-
2017
- 2017-08-03 US US15/668,236 patent/US10188621B2/en active Active
-
2018
- 2018-12-06 US US16/212,428 patent/US10744105B2/en active Active
-
2020
- 2020-07-30 US US16/943,558 patent/US11395809B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG153039A1 (en) | Crystalline polymorphic forms of monosodium n-[8- (2hydroxybenzoyl)amino]caprylate | |
HK1093483A1 (en) | Polymorphic form of n- | |
IL176141A0 (en) | Crystalline forms of valacyclovir hydrochloride | |
IL172006A0 (en) | Novel crystalline forms of valacyclovir hydrochloride | |
RS20130524A3 (en) | PROCEDURE FOR OBTAINING AMINO CROTONYL UNITS | |
HK1075044A1 (en) | Crystalline polymorphic form of irinotecan hydrochloride | |
EP1717225A4 (de) | Bicyclische amidderivate | |
HK1209752A1 (en) | Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents | |
EP1804582A4 (de) | Polymorphe formen von tadalafil | |
IL172004A0 (en) | Polymorphic forms of ziprasidone hci and processes for their preparation | |
IL192360A0 (en) | Crystalline polymorphic forms of olopatadine hydrochloride and processes for their preparation | |
IL181185A0 (en) | Novel polymorphs of azabicyclohexane | |
IL176953A0 (en) | Polymorphic forms of nateglinide | |
HK1148527A1 (en) | Amine salt of carbostyril derivative | |
AU2003232719A1 (en) | Novel crystalline forms of valacyclovir hydrochloride | |
IL166592A0 (en) | Novel crystalline forms of gatifloxacin | |
IL165115A0 (en) | Novel crystalline forms of gatifloxacin | |
EP1804796A4 (de) | Aminosubstituierte aryloxybenzylpiperidin-derivate | |
IL174969A0 (en) | Crystalline forms of (+)-and (-) erythro-mefloquine hydrochloride | |
EP1632476A4 (de) | Säureadditionssalz eines carbazuckeraminderivats | |
IL166308A0 (en) | Polymorphic forms of nateglinide | |
PL373802A1 (en) | Polymorphic forms of phenyl oxazolidinone derivatives | |
IL165690A0 (en) | Novel crystalline forms of gatifloxacin | |
IL179151A0 (en) | Synthesis of amino acid keto-epoxides | |
SI1487840T1 (sl) | Kristalinična polimorfna oblika irinotekan hidroklorida |